SureTrader Advertisement Advertisement Advertisement
Home > Boards > US Listed > Biotechs >

Bioheart, Inc. (BHRT)

Add BHRT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 10/8/2015 3:25:51 PM - Followers: 166 - Board type: Free - Posts Today: 8


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


MyoCell SDF-1 



Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell.

The MyoCath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart. 

Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells.  Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.  


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BHRT News: Statement of Changes in Beneficial Ownership (4) 10/07/2015 04:01:43 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 10/05/2015 09:51:51 AM
BHRT News: Current Report Filing (8-k) 10/02/2015 04:02:04 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 10/01/2015 09:01:46 AM
BHRT News: Information Statement - All Other (definitive) (def 14c) 09/08/2015 04:01:54 PM
#16429   What are the co salaries compared to the EquityElite 10/08/15 03:25:50 PM
#16428   He can write what he want runcaly 10/08/15 02:46:45 PM
#16427   Relentless!!! gypsydoc 10/08/15 02:40:21 PM
#16426   He deserves it more than I can wrote ... runcaly 10/08/15 02:31:08 PM
#16425   Quote BS LOL, "It use to trade on Captain Kirk 10/08/15 12:47:23 PM
#16424   BHRT PINK SHEET DEMOTION NOTICE: Captain Kirk 10/08/15 12:16:40 PM
#16423   BHRT success is not reflective of their current EquityElite 10/08/15 12:08:36 PM
#16422   BHRT PINK SHEETS, UH OH !!! Captain Kirk 10/08/15 10:43:26 AM
#16421   I hope they keep the OTCQB status in EquityElite 10/07/15 03:09:09 PM
#16420   Bid .0012 now, w/ 2 MILLION @ .0011 Captain Kirk 10/07/15 12:42:01 PM
#16419   Quote, "Why can't BHRT raise the AS instead Captain Kirk 10/07/15 10:45:23 AM
#16418   It's possible since Dr.Murphy picked up about 9.2 ihubmoney 10/07/15 10:06:39 AM
#16417   Why can't BHRT raise the AS instead of EquityElite 10/07/15 09:22:07 AM
#16416   Looks like it's going to trips Chunky Salsa 10/07/15 08:47:33 AM
#16415   Is the AS max out? I thought they EquityElite 10/06/15 11:02:23 PM
#16414   Announce RS, share price plummets Pick up millions photo4u 10/06/15 09:59:25 PM
#16413   Anyone know about the scheduled RS? EquityElite 10/06/15 04:35:43 PM
#16412   3.3 MILLION on Bid @ .0012 HOLY COW !! Captain Kirk 10/06/15 01:43:10 PM
#16411   BKRT MM with 10k block, that's a new EquityElite 10/06/15 10:42:25 AM
#16410   .0015 UH OH, this doesn't look good????? Captain Kirk 10/06/15 10:07:04 AM
#16409   Well, that didn't last long LOL !!!! Captain Kirk 10/05/15 11:46:48 AM
#16408   Is US Stemcell progressing their trials? How Starbase9 10/05/15 08:21:01 AM
#16407   ANOTHER MAGNA DILUTION "note" LOL !!! Captain Kirk 10/02/15 07:08:00 PM
#16406   Sunrise, FL – October 2, 2015 – US andyshow 10/02/15 04:31:10 PM
#16404   Sean & Bryan Collins, who you refer to gypsydoc 10/02/15 08:39:23 AM
#16403   Quote LOL, "And Sean Collins too. Bryans brother." Captain Kirk 10/01/15 11:02:24 PM
#16402   And Sean Collins too. Bryans brother. gypsydoc 10/01/15 10:44:37 PM
#16401   Quote BS LOL, "I think Kirk is right... Captain Kirk 10/01/15 10:09:35 PM
#16400   I think Kirk is right... Bryan Collins and Investaholic33 10/01/15 09:59:56 PM
#16399   Glad I made you laugh... I thought the gypsydoc 10/01/15 05:51:08 PM
#16398   Quote LOL, "With all of the extraordinary movement Captain Kirk 10/01/15 05:22:23 PM
#16397   With all of the extraordinary movement occurring with gypsydoc 10/01/15 04:37:39 PM
#16396   So when this useless trash going to do ihubmoney 10/01/15 04:12:25 PM
#16395   Interesting article on FINRA and massive R/S reverse splits: Captain Kirk 10/01/15 01:26:11 PM
#16394   Didn't think I'd see the day. EquityElite 09/30/15 03:14:05 PM
#16393   This useless piece of SH*t is nothing but ihubmoney 09/30/15 01:43:15 PM
#16392   Bid hit .0012, HOLY FREAKING COW?????? Captain Kirk 09/30/15 01:21:14 PM
#16391   Bid collapsing back to .0016, HOLY COW !! Captain Kirk 09/30/15 09:44:21 AM
#16390   .0016 NEW ALL, ALL TIME LOW TODAY !! Captain Kirk 09/29/15 05:48:41 PM
#16389   .0016 on the BID I see. Captain Kirk 09/29/15 03:08:53 PM
#16388   .0016 on the BID I see. EquityElite 09/29/15 01:58:14 PM
#16387   Well, that didn't last long LOL !!! Captain Kirk 09/29/15 12:19:05 PM
#16386   Quote, "I thought the RS was taking place Captain Kirk 09/28/15 11:41:37 PM
#16385   I thought the RS was taking place on EquityElite 09/28/15 11:30:28 PM
#16384   A ZERO VOLUME OPEN NOW, LOL????????? Captain Kirk 09/28/15 10:40:08 AM
#16383   BMAK sends another to RS. And anoher one BigAlBalbosci 09/27/15 02:27:37 AM
#16382   Can they sell shares on the open market EquityElite 09/26/15 11:28:30 AM
#16381   This closed low today. Let's see how it EquityElite 09/25/15 10:36:52 PM
#16380   Hit .0018 today, DOWN 30%, SOLID RED !! Captain Kirk 09/25/15 04:24:52 PM
#16379   Quote LOL, "Looks like this is recovering a Captain Kirk 09/25/15 10:46:25 AM